Topics

"Synpromics Ltd∨derfield=date∨derval=DESC" News Stories

18:58 EDT 19th July 2019 | BioPortfolio

Here are the most relevant search results for "Synpromics Ltd∨derfield=date∨derval=DESC" found in our extensive news archives from over 250 global news sources.

More Information about Synpromics Ltd∨derfield=date∨derval=DESC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Synpromics Ltd∨derfield=date∨derval=DESC for you to read. Along with our medical data and news we also list Synpromics Ltd∨derfield=date∨derval=DESC Clinical Trials, which are updated daily. BioPortfolio also has a large database of Synpromics Ltd∨derfield=date∨derval=DESC Companies for you to search.

Showing "Synpromics derfield date derval DESC" News Articles 1–25 of 4,900+

Friday 19th July 2019

DionyMed Signs Definitive Agreements With Innovative Industrial Properties to Finance a Southern California Cannabis Campus Acquisition, Expanding DYME’s Direct-to-Consumer and Distribution Platform Statewide

DionyMed Brands Inc. (“DionyMed” or “Company”) (CSE: DYME)(OTCQB:DYMEF), a multi-state cannabis brands platform, announced today that it has signed a definitive agreement to acquire select assets from MM Esperanza 2 LLC, doing business as “MMAC,” and MMAC’s 1.83 acre Los Angeles cannabis campus. This acquisition marks the expansion of DionyMed’s operational capabilities in Souther...


Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., July 19, 2019 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the … Continue reading →

Tandem Diabetes Care to Announce Second Quarter 2019 Financial Results on August 1, 2019

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2019 results after the financial markets close on Thursday, August 1, 2019. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its second quarter 2019 financial and operatin...


July 19 Financial Quick Takes: Amarin raises cash ahead of Vascepa PDUFA date, plus Atara, Sunstone and Forendo

Time-to-Treatment Discontinuation of Therapy in NSCLC Trials

Is therapy start date to date of discontinuation or death a potential efficacy endpoint for real-world evidence trials? Annals of Oncology

Acerus Announces Closing of US$5 Million Secured Term Loan

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million subordinated secured term loan facility (“the Loan”) with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus.(1) The Loan is subordinated to the existing US$9 mill...

Aktionäre von McDonalds erhalten seit 1976 eine Dividende

Die amerikanische Schnellrestaurantkette McDonalds Corp. (ISIN: US5801351017, NYSE: MCD) zahlt am 17. September 2019 eine Quartalsdividende von 1,16 US-Dollar an die Aktionäre aus (Record date ist ...

Unser Robot zum Dow: Unverändert, Merck und Exxon je 4 Tage im Plus

Der Dow Jones gewann am Donnerstag 0,01% auf 27222,97 Punkte. Year-to-date liegt der Dow Jones nun 16,7% im Plus. Es gab bisher 77 Gewinntage und 60 Verlusttage. Auf das Jahreshoch fehlen 0,5%, vom...

Thursday 18th July 2019

Manhattan Scientifics Announces Breakthrough Device for Detection of Cancer

Manhattan Scientifics Inc.’s (OTC: QB MHTX) former wholly-owned subsidiary that was initially funded by MHTX, Imagion Biosystems Ltd (ASX:IBX) over a nine-year period has received confirmation from the Food and Drug Administration (FDA) that the MagSense System and Test for staging

Genentech partners with Skyhawk on RNA splicing modulators

In its third partnership so far in 2019, and fourth overall to date, Skyhawk Therapeutics Inc. granted Roche’s Genentech In...

Human medicines European public assessment report (EPAR): Ucedane, carglumic acid, Hyperammonemia,Amino Acid Metabolism, Inborn Errors, Date of authorisation: 23/06/2017, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Ucedane, carglumic acid, Hyperammonemia,Amino Acid Metabolism, Inborn Errors, Date of authorisation: 23/06/2017, Revision: 4, Status: Authorised

UnitedCoatings Group Announces Acquisition of CoorsTek Medical

Acquisition Broadens UnitedCoatings’ Capabilities to Offer Comprehensive Supply Chain Solutions UnitedCoatings Group, together with its medical division (Eurocoating SpA, Surface Dynamics, NanoSurfaces Industries, Anteco and Eurocoating Medical Technology Wuxi), a leading global supplier of integrated contract manufacturing solutions to medical device OEMs, announced today that, after its acqu...

Phase II/III Study Trends and Market Outlook 2018-2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Phase II/III Study Trends and Market Outlook (2018-2022)” report has been added to ResearchAndMarkets.com’s offering. Keeping up-to-date with the evolving pharmaceutical market is no easy task. The constant flow of newsletters hitting our inboxes is almost too much … Continue reading →

Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Radionuclide Imaging,Alzheimer Disease, Date of authorisation: 20/02/2014, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Radionuclide Imaging,Alzheimer Disease, Date of authorisation: 20/02/2014, Revision: 15, Status: Authorised

Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - two common nerve agents

Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced that it was granted Patent No. 238946 for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate...

Acorda Second Quarter 2019 Update:  Webcast/Conference Call Scheduled for August 1, 2019

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast to report its second quarter 2019 update and financial results on Thursday, August 1 at 4:30 p.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) or (734) 385-2616 (international) and reference the access code 2287274. The presentation will be available on the Investors section of w...

Corindus Adds Two New CorPath GRX Installations to HCA Healthcare Facilities

One of the nation’s largest hospital networks adopts vascular robotic technology in multiple hospital locations to treat patients in need of cardiovascular care Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has ins

Senseonics Announces Pricing of Public Offering of Common Stock

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of a registered underwritten public offering of 22,727,273 shares of its common stock at a price to the public of $1.10 per share. The gross proceed...

Senseonics Announces Pricing of $82.0 Million 5.25% Convertible Senior Notes Due 2025

Senseonics Holdings, Inc. (“Senseonics” or the “Company”) (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of an $82.0 million aggregate principal amount of 5.25% convertible senior notes due 2025 (the “2025 note...

Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering

SAN FRANCISCO, CA / ACCESSWIRE / July 19, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $14.4 million before deducting unde...

Wednesday 17th July 2019

Potential benefits and risks of using e-cigarettes

While cigarette use for high school students is at an all-time low (8%), 21% of students in the United States report using e-cigarettes in the past month, which is the highest level to date.

Rising CO2, climate change projected to reduce availability of nutrients worldwide

(International Food Policy Research Institute) The most comprehensive synthesis of climate change impacts on the global availability of nutrients to date finds that, over the next 30 years, climate change and higher CO2 could significantly reduce the availability of critical nutrients, representing another challenge to global development and the fight to end undernutrition.

5 Top NASDAQ Biotech Stocks Year-to-Date

The first half of 2019 is done, which means it's time to look back on the top performing NASDAQ biotech stocks year-to-date. The post 5 Top NASDAQ Biotech Stocks Year-to-Date appeared first on Investing News Network.

Agilent Technologies, Inc. Strategy, SWOT and Corporate Finance Report [Report Updated: 11032019] Prices from USD $175

Agilent Technologies, Inc. Strategy, SWOT and Corporate Finance ReportSummaryAgilent Technologies, Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.Key HighlightsAgilent Technologi...

Sesen Bio Announces Retirement of Leslie L. Dan

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Leslie L. Dan has retired from the Company's Board of Directors, effective July 16, 2019. With the retirement of Mr. Dan, the Company’s Board of Directors will be comprised of five directors of which four are independent. The Com...


Quick Search

News Quicklinks